If you have been reading about Reverse-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-07. Numbers and descriptions here follow the published literature rather than marketing material.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Algae are used as foods in many countries: China consumes more than 70 species, including fat choy, a cyanobacterium considered a vegetable; Japan, over 20 species such as nori and aonori; Ireland, dulse; Chile, cochayuyo. Laver is used to make laverbread in Wales, where it is known as bara lawr. In Korea, green laver is used to make gim. Some of the most commonly used microalgae as food are:
=== Associations with pathologies === Gestational trophoblastic disease like hydatidiform moles ("molar pregnancy") or choriocarcinoma may produce high levels of βhCG due to the presence of syncytiotrophoblasts, part of the villi that make up the placenta, and despite the absence of an embryo. This, as well as several other conditions, can lead to elevated hCG readings in the absence of pregnancy. hCG levels are also a component of the triple test, a screening test for certain fetal chromosomal abnormalities/birth defects. High hCG levels in the maternal serum could suggest Down syndrome, potentially due to continued hCG production by the placenta beyond the first trimester. A study of 32 normal pregnancies came to the result that a gestational sac of 1–3 mm was detected at a mean hCG level of 1150 IU/L (range 800–1500), a yolk sac was detected at a mean level of 6000 IU/L (range 4500–7500) and fetal heartbeat was visible at a mean hCG level of 10,000 IU/L (range 8650–12,200).
In the Philippines, circumcision is known as "tuli" and is generally viewed as a rite of passage. An overwhelming majority of Filipino men are circumcised. Often this occurs in April and May, when Filipino boys are taken by their parents. The practice dates back to the arrival of Islam in 1450. Pressure to be circumcised is even in the language: one Tagalog profanity for "uncircumcised" is supot, meaning "coward". A circumcised eight- or ten-year-old is no longer considered a boy and is given more adult roles in the family and society.
1885: Berries from Norfolk, Virginia, were shipped by refrigerator car to New York. 1887: Parker Earle joined F.A. Thomas of Chicago in the fruit shipping business. The company owned 60 ice-cooled railcars by 1888, and 600 by 1891. 1888: Armour & Co. shipped beef from Chicago to Florida in a car cooled by ethyl chloride-compression machinery. Florida oranges were shipped to New York under refrigeration for the first time. 1889: The first cooled shipment of fruit from California was sold on the New York market. 1898: Russia's first refrigerator cars entered service. The country's inventory reached 1,900 by 1908, 3,000 two years later, and peaked at approximately 5,900 by 1916. The cars were used mainly for transporting butter from Siberia to the Baltic Sea, a 12-day journey. 1899: Refrigerated fruit traffic within the U.S. reached 90,000 short tons (81,647 t; 80,357 long tons) per year; Transport from California to New York averaged 12 days in 1900. 1901: Carl von Linde equipped a Russian train with a mobile, central mechanical refrigeration plant to distribute cooling to cars carrying perishable goods. Similar systems were used in Russia as late as 1975. 1905: U.S. traffic in refrigerated fruit reached 430,000 short tons (390,089 t; 383,929 long tons). As refrigerator car designs became standardized, the practice of indicating the "patentee" on the sides was discontinued. 1907: The Pacific Fruit Express began operations with more than 6,000 refrigerated cars, transporting fruit and vegetables from Western producers to Eastern consumers. U.S.
Sources: en.wikipedia.org
== Education == Frank completed her M.D. and Ph.D. in biochemistry at the University of Pennsylvania. She completed a clinical pathology residency at the Brigham and Women's Hospital. During her postdoctoral research fellowship in immunology, she focused on V(D)J recombination in developing lymphocytes in the Howard Hughes Medical Institute laboratory of Frederick Alt at the Boston Children's Hospital. As a faculty member, her studies included DNA repair mechanisms relevant to both cancer and immunology, followed by microbiological investigations of Staphylococcus aureus and enterobacteriaceae.
== Signal peptide as a therapeutic target == Signal peptide is a potential (therapeutic) antiviral target. The stable signal peptides (SSPs) of mammarenavirus viral glycoprotein precursors re-associate with mature spike proteins after their co-translational cleavage. SSPs with a penultimate N-terminus glycine are a target for NMT inhibitors, which inhibit the myristoylation of signal peptides and target the signal peptide for proteasomal degradation, affecting virus–cellular fusion.
== History == ITGA1 was first identified in 1986 as a Very Late Antigen-1 (VLA-1), a surface protein expressed on activated T lymphocytes. Later studies demonstrated that VLA-1 corresponds to the α1 integrin subunit, which pairs with the β1 integrin subunit to fom the α1β1 heterodimer, a receptor for collagen and laminin. During the early 1990s, cloning of the human ITGA1 gene enabled detailed characterization of its structure and tissue distribution. Structural studies later identified the α1 subunit as one of the integrins containing an inserted von Willebrand factor A domain responsible for collagen recognition. More recent research has expanded the biological significance of ITGA1 beyond cell adhesion to include roles in mechanotransduction, immune regulation, fibrosis, and cancer, leading to growing interest in ITGA1 as a potential therapeutic target.
Sources: en.wikipedia.org
An independence, considered imposed (favoring the historiographical thesis of independence granted, and not achieved or conceived) and very probably against the will of the Peruvians (from which previous declarations of independence would have already emerged, such as the Cuzco Rebellion, later repressed by the Peruvians themselves loyal to the Viceroyalty, and without the need for the intervention of an invading army), based on some phrases such as:
The 'Fortuna' GM potato variety developed by BASF was made resistant to late blight by introgressing two resistance genes, blb1 and blb2, from S. bulbocastanum, a wild potato native to Mexico. Rpi-blb1 is a nucleotide-binding leucine-rich repeat (NB-LRR/NLR), an R-gene-produced immunoreceptor. In October 2011, BASF requested cultivation and marketing approval as a feed and food from the EFSA. In 2012, GMO development in Europe was stopped by BASF. In November 2014, the United States Department of Agriculture (USDA) approved a genetically modified potato developed by Simplot, which contains genetic modifications that prevent bruising and produce less acrylamide when fried than conventional potatoes; the modifications do not cause new proteins to be made, but rather prevent proteins from being made via RNA interference. Genetically modified varieties have met public resistance in the U.S. and in the European Union.
It may also be possible to generate isotopes in the island of stability such as 298Fl in multi-nucleon transfer reactions in low-energy collisions of actinide nuclei (such as 238U and 248Cm). This inverse quasifission (partial fusion followed by fission, with a shift away from mass equilibrium that results in more asymmetric products) mechanism may provide a path to the island of stability if shell effects around Z = 114 are sufficiently strong, though lighter elements such as nobelium and seaborgium (Z = 102–106) are predicted to have higher yields. Preliminary studies of the 238U + 238U and 238U + 248Cm transfer reactions have failed to produce elements heavier than mendelevium (Z = 101), though the increased yield in the latter reaction suggests that the use of even heavier targets such as 254Es (if available) may enable production of superheavy elements. This result is supported by a later calculation suggesting that the yield of superheavy nuclides (with Z ≤ 109) will likely be higher in transfer reactions using heavier targets. A 2018 study of the 238U + 232Th reaction at the Texas A&M Cyclotron Institute by Sara Wuenschel et al. found several unknown alpha decays that may possibly be attributed to new, neutron-rich isotopes of superheavy elements with 104 < Z < 116, though further research is required to unambiguously determine the atomic number of the products. This result strongly suggests that shell effects have a significant influence on cross sections, and that the island of stability could possibly be reached in future experiments with transfer reactions.
Livagen is a tetrapeptide with the sequence KEDA or Lys-Glu-Asp-Ala. It is one of a number of small peptides developed in Russia in the late 1990s and early 2000s which have antiinflammatory and purported anti-aging effects, and are now widely sold over the internet as anti-aging products though with relatively limited evidence to support these claims.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
Long-term storage is usually at minus 20 to minus 80 degrees Celsius in a sealed, desiccated container. Working aliquots can be held briefly at 2 to 8 degrees Celsius.